Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 78

  • 1 133 clinical trials
  • 489 recruiting
  • 474 conditions
  • 28 countries

Conditions in this area

474 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic106Crohn's disease94Colorectal cancer90Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma40Adenocarcinoma pancreas36Pancreatic carcinoma metastatic35Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome31Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Colorectal adenocarcinoma16Endometrial cancer16+450

Clinical trials in Gastrointestinal disorders

1 133 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 133 clinical trials

Rectal cancer

Not recruiting

Study on Induction Chemotherapy with Irinotecan, Folinic Acid, Fluorouracil, and Oxaliplatin for Patients with High-Risk Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Catharina Ziekenhuis Stichting

Colitis ulcerative+1

Not recruiting

Study on the Long-term Safety of Vedolizumab for Children with Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Immunoglobulin G4 related disease

Not recruiting

Study on the Effectiveness of Inebilizumab for Patients with IgG4-Related Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Coeliac disease

Not recruiting

Study on the Effects of KAN-101 and Sodium Chloride in Adults with Celiac Disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:KAN-101
  • Sponsor:Kanyos Bio Inc.

Gastrooesophageal cancer+1

Not recruiting

Study of Retifanlimab, Capecitabine, and Oxaliplatin for First-Line Treatment in Patients with Metastatic Esophagogastric Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Amsterdam UMC Stichting

Pancreatic carcinoma

Not recruiting

Study on the Effectiveness and Safety of Immunotherapy with Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Colorectal adenocarcinoma

Not recruiting

Study on Encorafenib, Cetuximab, and FOLFIRI for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer After Progression on Encorafenib and Cetuximab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Colorectal cancer metastatic

Not recruiting

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Gastrooesophageal reflux disease

Not recruiting

Study on the Safety and Effectiveness of Dexlansoprazole for Treating Nonerosive GERD in Children Aged 2 to 11 Years

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Dexlansoprazole
  • Sponsor:Takeda Development Center Americas Inc.

Erosive oesophagitis

Not recruiting

Study on Dexlansoprazole for Treating and Maintaining Healing of Erosive Esophagitis in Children Aged 2 to 11 Years

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Dexlansoprazole
  • Sponsor:Takeda Development Center Americas Inc.

Oesophageal squamous cell carcinoma

Not recruiting

Study of Durvalumab with Chemoradiation Therapy for Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Oesophageal carcinoma+1

Not recruiting

Study on Tocilizumab for Patients with Esophageal Cancer to Improve Chemoradiotherapy Outcomes

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Amsterdam UMC Stichting

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil207 clinical trialsOxaliplatin197 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate69 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate53 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.